Precision Neuroscience Raises $250 Million to Advance Brain-Computer Interface Technology

Precision Neuroscience, a brain-computer interface company, closed an oversubscribed $250 million Series D round led by Pershing Square and the Ackman Oxman Institute, with participation from Duquesne Family Office, B Capital, ARK Invest, Invus, Mubadala Capital, Mirae Asset Capital, Korea Investment Partners, Hitachi Ventures and JSL Health Capital, among others. The round brings the company's total capital raised since its 2021 founding to $430 million and will go toward expanding its clinical program, advancing its Layer 7 Cortical Interface through further FDA review, and building out infrastructure for commercialization.

What Precision Neuroscience Builds

Precision Neuroscience builds an ultra-thin, film-based brain-computer interface called the Layer 7 Cortical Interface, designed to sit directly on the surface of the brain without penetrating cortical tissue, a structural difference from implant designs that insert electrodes into brain matter. The company has already logged more than 100 patient procedures using the technology across 18 medical institutions, received FDA clearance for the Layer 7 device, struck a commercial partnership with Medtronic, and built a wholly owned MEMS manufacturing facility in Texas rather than outsourcing chip production to a third party.

Why This Round Signals a Market Shift, Not Just a Big Check

The investor list here is the more unusual signal than the dollar figure. Pershing Square and the Ackman Oxman Institute are not traditional life-sciences investors, and their presence alongside more conventional healthcare and deep-tech backers like Invus and JSL Health Capital suggests brain-computer interface technology is starting to attract generalist capital that previously stayed on the sidelines of a category defined mostly by long regulatory timelines and unproven commercial paths. That shift typically only happens once a company has cleared enough real-world validation, in this case FDA clearance plus over 100 completed procedures and a named commercial partner, to look more like a de-risked infrastructure bet than a speculative science project. A round this size, oversubscribed rather than merely filled, also indicates the company had leverage to be selective about which investors it let in, a position few brain-computer interface companies have historically been able to negotiate from.

What This Means for Founders

Precision Neuroscience's raise is a useful marker for any founder building in medical devices, neurotechnology, or another category with a genuinely long regulatory runway: the milestones that unlock generalist, non-traditional capital are concrete and sequential, a real regulatory clearance, a real commercial partnership, and a real base of completed procedures, not user growth or narrative momentum alone. A founder in a similarly regulated category should treat FDA clearance and a first anchor commercial partner as the two events most likely to change who is willing to write a check, and should sequence fundraising conversations with generalist or crossover investors to follow those milestones rather than precede them. The decision to build owned manufacturing capacity in-house, rather than relying on a contract manufacturer, is also worth studying: for a hardware-dependent medtech company it can be the difference between controlling your own supply chain at scale and being at the mercy of someone else's production timeline once demand actually arrives. Founders building in neurotechnology or medical devices looking for investors with an active thesis in the space can browse healthtech investors on AngelLinx.

Find investors who are actively deploying by creating your pitch listing on AngelLinx @ angellinx.ai/register.

AngelLinx Intelligence | angellinx.ai